Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Oct 2016. Module: Canada Health Infoway English module (core metadata concept)
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 138041000087115 | HibTITER 10 micrograms per 0.5 milliliter solution for injection Lederle-Cyanamid Canada Inc. (real clinical drug) | en | Fully specified name | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| 71631000087117 | Hib HibTITER LL | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| 71651000087114 | HibTITER 10 micrograms per 0.5 milliliter solution for injection Lederle-Cyanamid Canada Inc. | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| HibTITER 10 micrograms per 0.5 milliliter solution for injection Lederle-Cyanamid Canada Inc. (real clinical drug) | est un(e) (attribut) | Haemophilus influenzae type b capsular polysaccharide antigen conjugated only vaccine product | true | Inferred relationship | Some | ||
| HibTITER 10 micrograms per 0.5 milliliter solution for injection Lederle-Cyanamid Canada Inc. (real clinical drug) | Plays role | Active immunity stimulant role (role) | true | Inferred relationship | Some | ||
| HibTITER 10 micrograms per 0.5 milliliter solution for injection Lederle-Cyanamid Canada Inc. (real clinical drug) | a une forme pharmaceutique (attribut) | forme pharmaceutique pour usage parentéral (forme pharmaceutique) | true | Inferred relationship | Some | ||
| HibTITER 10 micrograms per 0.5 milliliter solution for injection Lederle-Cyanamid Canada Inc. (real clinical drug) | Has supplier | Lederle-Cyanamid Canada Inc. (supplier) | true | Inferred relationship | Some | ||
| HibTITER 10 micrograms per 0.5 milliliter solution for injection Lederle-Cyanamid Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Antigen of Haemophilus influenzae type b capsular polysaccharide polyribosylribitol phosphate conjugated to Corynebacterium diphtheriae cross-reacting material 197 protein (substance) | true | Inferred relationship | Some | 1 | |
| HibTITER 10 micrograms per 0.5 milliliter solution for injection Lederle-Cyanamid Canada Inc. (real clinical drug) | est un(e) (attribut) | Product manufactured as parenteral dose form (product) | true | Inferred relationship | Some | ||
| HibTITER 10 micrograms per 0.5 milliliter solution for injection Lederle-Cyanamid Canada Inc. (real clinical drug) | Count of base of active ingredient | un | false | Inferred relationship | Some | ||
| HibTITER 10 micrograms per 0.5 milliliter solution for injection Lederle-Cyanamid Canada Inc. (real clinical drug) | est un(e) (attribut) | Haemophilus influenzae Type b vaccine | false | Inferred relationship | Some | ||
| HibTITER 10 micrograms per 0.5 milliliter solution for injection Lederle-Cyanamid Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Haemophilus influenzae type b vaccine (substance) | false | Inferred relationship | Some | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR